Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

Summary

This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.

Timeline

Start

2023-10-10

Primary completion

2025-02-12

Completion

2025-02-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision. Not related to safety concern.”

Drugs

Indications